

Loma Linda University (USA) will study Hybrigenics' inecalcitol in preclinical models of FLT3-mutated Acute Myeloid Leukemia

Hybrigenics (Euronext Growth Paris - FR0004153930 – ALHYG) and its subsidiaries that constitute the branch DMS Biotech of DMS Group, is pleased to announce that **inecalcitol** will be studied by Prof. Huynh Cao's team of researchers, from Loma Linda University, California, USA, in preclinical cellular and animal models of a subgroup of **acute myeloid leukemia (AML)** with **FLT3 mutations**. Combinations of inecalcitol with FLT3 inhibitors, such as quizartinib or midostaurin, will also be studied.

Prof. Cao said: "In our preliminary study, we found that high dose vitamin D works extremely well on FLT3 cell lines and patients' samples as well as mouse models. I have the idea that inecalcitol can be still applied to FLT3-mutated AML".

As a reminder, Hybrigenics owns a rich patent portfolio on inecalcitol and ubiquitin-specific proteases (USP7 and 8) thanks to the historical activities of the company related the research and development programs on these two drugs. All together, these programs include more than 60 patents active in 16 countries.

Hybrigenics is listed on the Euronext Growth market of Euronext Paris

ISIN: FR0004153930

Ticker: ALHYG



HYBRIGENICS

Julien Gauthier

Managing Director

Phone: +33 (0)9 67 50 12 98